Non-Muscle Invasive Bladder Cancer (NMIBC) Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) - DelveInsight | CG Oncology (Cretostimogene), Abraxis, Asieris, AstraZeneca, ImmunityBio, Incyte, Janssen, Vaxiion

The Non-Muscle Invasive Bladder Cancer (NMIBC) market is witnessing significant evolution with the introduction of novel therapies and advancements in diagnostic techniques, paving the way for more personalized treatment approaches and improved patient outcomes. Rapid research developments and increasing awareness are reshaping the landscape, offering new avenues for effective management of this condition.

DelveInsight's "Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, Epidemiology, and Market Forecast 2034" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Non-Muscle Invasive Bladder Cancer Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Non-Muscle Invasive Bladder Cancer therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current Non-Muscle Invasive Bladder Cancer treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Non-Muscle Invasive Bladder Cancer (NMIBC): An Overview
Non-muscle invasive bladder cancer (NMIBC) is cancer of the bladder. NMIBC is a cancer that grows only in the thin tissue on the inside surface of the bladder. With NMIBC, the bladder muscle is not involved, and the tumor does not spread outside the bladder.

There are a number of things that may increase the risk of getting bladder cancer including smoking, working in places that make plastics, paints, leather, and rubber, cancer drugs, radiation to the pelvis, and genes. Blood in the urine is the most common symptom of bladder cancer, which is often painless. Other symptoms of NMIBC include frequent and urgent urination, pain when you pass urine, pain in your lower abdomen, and back pain.

The best treatment for NMIBC is early diagnosis and early care. Treatment will also depend on the stage and the growth of cancer. Treatments for non-muscle invasive bladder cancer include cystoscopic transurethral resection of the bladder tumor (TURBT), intravesical therapy, and surgery. If these options fail to treat the cancer, your doctor may recommend removing the complete bladder.

FDA has approved many drugs for the treatment of bladder cancer but to date there are only two drugs which are being given for the treatment of NMIBC which include KEYTRUDA and ADSTILADRIN, approved in 2020 and 2022, respectively.

Non-Muscle Invasive Bladder Cancer (NMIBC) Market Key Facts
• The Non-Muscle Invasive Bladder Cancer (NMIBC) Market size in the US was estimated to be USD 1,700 million in 2023.
• The total Non-muscle invasive bladder cancer market size in EU4 and the UK was estimated to be nearly USD 800 million in 2023, which is expected to grow during the forecast period.
• Among the 7MM, the US accounted for the highest number of cases in 2023, with around 600,000 prevalent cases, these cases are expected to increase during the forecast period.
• Among EU4 and the UK, the total prevalent cases of NMIBC were maximum in Italy, while the lowest number of cases were in France in 2023.
• Among cases categorized by risk level, the highest number belonged to the intermediate-risk category, whereas the lowest number was associated with the high-risk category.
• According to the estimates, in Japan, it is observed that NMIBC was most prevalent in the 70-89 age group, accounting for approximately 60% of total cases in 2023.
• In Japan, stage-specific cases of NMIBC were highest in the Ta stage, accounting for approximately 60% in 2023.

Get a Detailed Overview of the Evolving Non-Muscle Invasive Bladder Cancer Market Trends @
https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Non-Muscle Invasive Bladder Cancer (NMIBC) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Non-Muscle Invasive Bladder Cancer therapies in the market. It also provides a detailed assessment of the Non-Muscle Invasive Bladder Cancer market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Non-Muscle Invasive Bladder Cancer drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Non-Muscle Invasive Bladder Cancer Market Will Grow by 2034 @
https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Non-Muscle Invasive Bladder Cancer Epidemiology
The epidemiology section covers detailed insights into the historical, and current Non-Muscle Invasive Bladder Cancer patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2034.

The Report Covers the Non-Muscle Invasive Bladder Cancer Epidemiology Segmented as -
• Prevalent cases of Bladder Cancer
• Age-specific Diagnosed Prevalence of NMIBC
• Diagnosed Prevalent cases of NMIBC
• Tumor stage-specific Diagnosed Prevalence of NMIBC
• Risk-specific Diagnosed Prevalence of NMIBC
• Grade-specific Diagnosed Prevalence of NMIBC

Get Key Insights Into the Evolving Non-Muscle Invasive Bladder Cancer Epidemiology Trends @
https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Non-Muscle Invasive Bladder Cancer Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Muscle Invasive Bladder Cancer market or expected to be launched during the study period. The analysis covers the market share by Non-Muscle Invasive Bladder Cancer drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Non-Muscle Invasive Bladder Cancer Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Non-Muscle Invasive Bladder Cancer Market @
https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Non-Muscle Invasive Bladder Cancer (NMIBC) Therapeutics Assessment
NMIBC remains a very challenging disease to treat, with high rates of recurrence and progression associated with current therapies. The high rates of progression and recurrence with current therapies for NMIBC necessitate lifelong active surveillance, making bladder cancer the most expensive cancer to treat from diagnosis to death, as well as driving the need for the development of new therapies in patients with NMIBC.

The current treatment regimen includes KEYTRUDA (pembrolizumab), ADSTILADRIN, surgery, intravesical immunotherapy (BCG), and intravesical chemotherapy. Intermediate- or high-risk NMIBC is generally treated with transurethral resection of bladder tumor (TURBT), followed by adjuvant BCG immunotherapy which is the gold standard treatment for reducing tumor recurrence rates and preventing subsequent stage progression. Stage 0 bladder cancer is most often treated with TURBT with fulguration followed by intravesical therapy within 24 h. Sometimes no further treatment is needed. Cystoscopy is then done every 3-6 months to watch for signs that cancer has come back. Valrubicin might be used if BCG stops working. However, not all experts agree on this treatment.

Several major pharma and biotech giants are developing therapies for Non-Muscle Invasive Bladder Cancer. Currently, UroGen Pharma is leading the therapeutics market with its Non-Muscle Invasive Bladder Cancer drug candidates in the most advanced stage of clinical development.

In December 2022, US FDA approved ADSTILADRIN (nadofaragene firadenovec-vncg), a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

On February 27, 2024, CG Oncology announced the first patient has been dosed in the PIVOT-006 Phase 3 clinical trial of cretostimogene for the treatment of patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Leading Companies in the Non-Muscle Invasive Bladder Cancer Therapeutics Market Include
Abraxis Bioscience, Asieris Pharmaceuticals, AstraZeneca, CG Oncolgy, Hamlet Pharma, ImmunityBio, Incyte Corporation, Janssen Pharmaceuticals, LIPAC Oncology, Prokarium, Rapamycin Holdings, Sasanlimab, Sesen Bio, Taizhou Hanzhong biomedical, Theralase Technologies, Vaxiion Therapeutics, Viralytics, UroGen Pharma, and many more.

Emerging and Marketed Non-Muscle Invasive Bladder Cancer Therapies Covered in the Report Include
Adstiladrin(nadofaragenefiradenovec/Syn3): FKD Therapies Oy/Ferring Pharmaceuticals, APL-1202: Asieris Pharmaceuticals, CG0070: CG Oncology, EG-70: enGene, Erdafitinib: Janssen Pharmaceuticals, Keytruda: Merck, N-803 (ALT-803): ImmunityBio/Altor Biosciences, PF-06801591: Pfizer, Sasanlimab (PF-06801591): Pfizer, TARA-002: Protara Therapeutics, TECENTRIQ: Roche, TL-532: Tollys, TLD 1433: Theralase Technologies, UGN-102: UroGen Pharma, VAX 014: Vaxiion Therapeutics, Vicinium: Viventia Bio/Sesen Bio, KEYTRUDA (pembrolizumab): MSD, ADSTILADRIN (nadofaragene firadenovec-vncg): Ferring Pharmaceuticals, and many more.

Learn More About the Emerging Therapies and key Companies in the Non-Muscle Invasive Bladder Cancer Therapeutics Market @
https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Non-Muscle Invasive Bladder Cancer Competitive Intelligence Analysis
4. Non-Muscle Invasive Bladder Cancer Market Overview at a Glance
5. Non-Muscle Invasive Bladder Cancer Background and Overview
6. Non-Muscle Invasive Bladder Cancer Patient Journey
7. Non-Muscle Invasive Bladder Cancer Epidemiology and Patient Population
8. Non-Muscle Invasive Bladder Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Non-Muscle Invasive Bladder Cancer Unmet Needs
10. Key Endpoints of Non-Muscle Invasive Bladder Cancer Treatment
11. Non-Muscle Invasive Bladder Cancer Marketed Products
12. Non-Muscle Invasive Bladder Cancer Emerging Therapies
13. Non-Muscle Invasive Bladder Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Non-Muscle Invasive Bladder Cancer Market Outlook (7 major markets)
16. Non-Muscle Invasive Bladder Cancer Access and Reimbursement Overview
17. KOL Views on the Non-Muscle Invasive Bladder Cancer Market.
18. Non-Muscle Invasive Bladder Cancer Market Drivers
19. Non-Muscle Invasive Bladder Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.